VT103, an analog of VT101, is an orally active and selective TEAD1 protein palmitoylation inhibitor. VT103 inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation, and disrupts interaction between YAP/TAZ and TEAD. VT103 can be used for the research of cancer.
体外研究
VT103 (HEK293T cells; 3 μM) appeares to be TEAD1-selective, as it does not block palmitoylation of TEAD2, TEAD3, or TEAD4. VT103 (NF2-deficient NCI-H226 cells; 3 mmol/L; 4 or 24 hours) selectively disrupts YAP–TEAD1 interaction.
VT103 results in the disappearance of palmitoylated TEAD1 with a concomitant increase in unpalmitoylated TEAD1.
VT103 shows an IC50 of 1.02 nM in YAP reporter assay.
体内研究
VT103 (0.3~10 mg/kg; p.o. once per day) blocks tumor growth even at 0.3 mg/kg.
Pharmacokinetics of VT103 in mice
Dose
IV
PO
7 mg/kg
T1/2 (hours)
Vdss (L/kg)
CI(mL/min/kg)
AUC 0-24 hours (μg*h/mL)
AUC 0-24 hours (μg*h/mL)
Oral availability (%)
Cmax (ng/mL)
C24 hours (ng/mL)
13.2
4.5
4.7
20.0
14.9
75
896 (1 hour)
340
Animal Model:
NCI-H226-tumor bearing mice
Dosage:
0.3~10 mg/kg
Administration:
P.o. once per day
Result:
Blocked tumor growth even at 0.3 mg/kg.
分子式
C18H17F3N4O2S
分子量
410.41
CAS号
2290608-13-6
运输条件
Room temperature in continental US; may vary elsewhere.